Olix "FDA Approval Granted for Clinical Phase 2a Trial of Non-Invasive Scar Treatment Therapy"
[Asia Economy Reporter Minji Lee] Olix announced on the 29th that it has received approval from the U.S. Food and Drug Administration (FDA) for a Phase 2a clinical trial plan to evaluate the efficacy of OLX100 as an adjuvant therapy to suppress recurrence after scar reconstruction surgery.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The target condition is hypertrophic scars. The company stated, "We will verify the efficacy and safety of OLX100 and proceed with the next phase of clinical trials based on this," adding, "This confirms the potential for developing a new treatment in the hypertrophic scar market, where no FDA-approved prescription drugs currently exist."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
